Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

This panel discussion examines emerging treatment options for patients with BRAF V600E-Mutated Metastatic Colorectal Cancer.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer following first-line failure. Find out what you need to know about the latest studies so you can provide the best care for your patients with this condition.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Scott Kopetz, MD, PhD
    Department of Gastrointestinal Medical Oncology
    UT MD Anderson Cancer Center
    Houston, TX

    Consulting Fees: Amal Therapeutics, Amgen,Bayer Health, Biocartis, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, EMDSerono, Genentech, Holy Stone,Karyopharm Therapeutics,Lilly, Merck, Navire, Novartis, Pierre Fabre, Redx Pharma, Roche, Symphogen
    Contracted Research (to Institution): Amgen, Array BioPharma, Biocartis, EMD Serono, Genentech/Roche, Guardant Health, Lilly, MedImmune, Novartis, Sanofi 
    Ownership Interest:
    MolecularMatch, Navire

    Prof. Eric Van Cutsem, MD, PhD
    University Hospitals Leuven
    Leuven, Belgium

    Consulting Fees: Array, Astra Zeneca, Bayer, Biocartis, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Pierre-Fabre, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex, Taiho
    Contracted Research: Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier

    Josep Tabernero, MD, PhD
    Head, Medical Oncology Department
    Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO)
    Barcelona, Spain 

    Consulting Fees: Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess appropriate treatment options for patients with BRAF V600E-mutated metastatic colorectal cancer who have received prior treatment 
    • Summarize key data related to the use of the doublet combination in the management of patients with BRAF V600E-mutated metastatic colorectal cancer 
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, primary care physicians, nurses, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free